



EU wide added value of EURIPID

Presentation ad 10th BoP Meeting 9 June 2022, Oslo

General Secretary Claudia Habl GÖG, AT and partners

EURIPID in a Nutshell

- Initiative dating back to 2009, following work done in the INFOPRICE initiative of the Transparency Committee.
- In response of MS calling for a routine instrument to access comparable price information the EC launched a call for proposals to create and maintain an electronic price database of pharmaceuticals for the use of EU public administrations and, if appropriate, other relevant stakeholders.
- EURIPID was founded as a voluntary, non-profit collaboration of the European pricing and reimbursement authorities for the mutual sharing of information regarding pharmaceutical pricing policies and prices of medicinal products.
- The EURIPID Collaboration consists of founding members, partners i.e. members from 26 countries, associated partners like the OECD and the EC. Since 2019 membership is restricted to European countries.
- Since its launch the EURIPID database is online for > 12 years and provides > 30 million data points.
- EURIPID is recognized as an operational tool and included in the work plan 2021-2023 of the Flagship initiative “National Competent Authorities on Pricing and Reimbursement (**NCAPR**). The group has been relaunched in 2021 as a flagship initiative of the Pharmaceutical Strategy for Europe.

Current Framework on EU level

- ❖ The **Pharmaceutical Strategy for Europe** mentions in the section ‘to *make medicines more affordable*’ that further engagement between MS and the Commission can foster transparency of price information, which can help countries to take better pricing and reimbursement decisions. Prices and pricing decisions influence access to cost-effective and affordable medicines. Moreover, pricing practices in the pharmaceutical sector can affect the functioning of internal market in the Union.

https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2173

<https://ec.europa.eu/competition/sectors/pharmaceuticals/report2019/index.html>

- ❖ The **EU Pharmaceutical sector inquiry** yielded, whilst fully acknowledging national choices, that pricing regulations may create room for misuse and unintended behaviour (e.g. hidden discounts on published price lists used for reference pricing).

https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_en.pdf

The growing number of contractual obligations in so-called Managed-Entry-Agreements (MEAs) which usually include provisions regarding the confidentiality of prices is an example of this.

- ❖ The **EU4Health Work Programme 2022** calls EURIPID for a proposal for an action that will contribute to the policy priority to implement the Pharmaceutical Strategy for Europe as it concerns the support Member States in national pricing and reimbursement policies

https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf

Our Mission

The members of the EURIPID collaboration are convinced that transparency is a way to ensure patients timely access to medicines.

Thus, we work together on a voluntary basis

- ❖ to make pricing procedures and prices of pharmaceuticals more transparent in Europe
- ❖ to share information that impacts the affordability and availability of medicines to patients (e.g., MEA, volumes) and
- ❖ to improve collaboration and communication among our members.

- ❖ Most comprehensive source on price records for pharmaceuticals
- ❖ Established governance structure with little burden on regular members
- ❖ Continuous exchange between members, EC services and project team
- ❖ Inclusion of products and information beyond the initial scope
- ❖ Technical Guidance on External Reference Pricing with 12 principles
- ❖ Standard operating procedures (SOP) on data standardisation
- ❖ 4-way data quality assurance system
- ❖ Knowledge broker and capacity builder towards members and international organisations
- ❖ Place for informal dialogue with stakeholders launched by a Joint Statement
- ❖ Scientific work (analysis and exchange with research community)

An important tool in the European pharmaceutical landscape

Our Major Achievements since 2010

Voice of participants

„A database of pharmaceutical prices is a practical example of voluntary co-operation between EU/EEA countries and the European Commission. It is a useful tool for competent authorities, and ultimately benefits payers and patients in increasing price transparency in this field.”

Helga Festøy, NoMA, Norway, Chair of the BoP

“Safeguarding affordable and sustainable access to high quality medicines forces payers – buyers – to engage in a societal dialogue to set preferences, make choices and decide on willingness to pay/invest in therapies. Comprehensive, comparable, correct and up to date information on the cost and price of medicines – the kind EURIPID delivers – is crucial for this task.”

Francis Aricks, RIZIV/INAMI, Belgium, Chair of Euripid Executive Committee

“The successful example of voluntary collaboration in the field of medicinal products between Member States.”

Ex-Commissioner for Health and Food Safety Vytenis Andriukaitis in his address to the European Council in 12/2017

EURIPID

Search

Queries

- Price changes
- New products
- Delisted products
- New ATCs
- Delisted ATCs
- First match

Downloads

2022 > Documents

Name ↓↑	Status ↓↑	Created By ↓↑	Created At ↓↑	Published At ↓↑
<input type="text"/>	All ▾		from date _____ to date _____	from date _____ to date _____
←				
EURIPID Achievements and Added Value_April2022.pdf	Active	Nóra Náduvvari	10-05-2022	11-05-2022
EURIPID_ROADMAP_Future_Scenario_Draft.docx	Active	Nóra Náduvvari	10-05-2022	11-05-2022
EURIPID_ROADMAP_Future_Scenarios_Annex_Methodology_Draft.pdf	Active	Nóra Náduvvari	10-05-2022	11-05-2022



Further reading



Thank you!

